Skip to main content
For Healthcare Professionals
Banner-Background

OVERALL POPULATION

JASCAYD® 18 mg improved survival as shown by a numerical reduction in the risk of death vs placebo at the end of trial analysis1

The key secondary endpoint (time to first acute IPF exacerbation, first hospitalization for respiratory cause, or death over duration of trial) was not met. The analyses of the secondary and further endpoints of time to death and time to progression were not part of confirmatory testing and are explorative in nature.2

Numerical reduction in the risk of death vs placebo at the end of trial analysis
Numerical reduction in the risk of death vs placebo at the end of trial analysis

IPF, idiopathic pulmonary fibrosis.

JASCAYD® improved survival as demonstrated by an early and sustained reduction in risk of death vs placebo at the end of trial analysis3

Early and sustained reduction in risk of death vs placebo at the end of trial analysis
Early and sustained reduction in risk of death vs placebo at the end of trial analysis

MONOTHERAPY

JASCAYD® 18 mg as monotherapy showed improved survival by a nominally significant reduction in risk of death at the end of trial analysis1

Nominally significant reduction in risk of death at the end of trial analysis
Nominally significant reduction in risk of death at the end of trial analysis

AF, antifibrotic.

Quicklinks

COMBINATION

JASCAYD® 18 mg with nintedanib improved survival shown by a numerical reduction in risk of death at the end of trial analysis1

JASCAYD® 18 mg with nintedanib improved survival
JASCAYD® 18 mg with nintedanib improved survival
Quicklinks

References

  1. Oldham JM, Azuma A, Kreuter M, et al. Effect of nerandomilast on clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF): data from final database lock of the FIBRONEER-IPF trial. Presented at: European Respiratory Society (ERS) International Congress; September 2025; Vienna, Austria. Poster available from: https://www.globalmedcomms.com/respiratory/ERS2025/Oldham1.

  2. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392(22):2193-2202.

  3. Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026;212(5):972-980.

MLR ID: PC-AE-102892
Expiry Date: 10/05/2028